genprowebdirectory
GEN Edge
Featured News
Multimedia
News
Insights
Trends for 2020
Trends for 2021
Trends for 2023
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
GEN Edge
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Videos
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Cell Signaling
Amino Acid That Delivers “Slow Down” Signal to Brain May Contribute…
Cancer
Preventing Metastasis with a STING
Artificial Intelligence
One AI Tool Bests Another in Enzyme Prediction Match
Cancer
How Incurable Melanoma Resists Treatment
AgBio
Food For Thought: Final Report from the AGBT Ag Meeting
Insights
All
Trends for 2020
Trends for 2021
Trends for 2023
Base Editing
One-Time Treatment: Base Editing Shows Promise vs. SMA
Drug Delivery
Nature’s Needle: Feng Zhang’s Team Re-engineers Bacterial “Syringes” for Programmable Protein…
Bioprocessing
Polymer Formulation to Improve Existing Antibiotics
Bioprocessing
Key Consideration for Going Digital
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
GEN Edge
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Drug Discovery
Seven Biopharma Trends to Watch in 2023
A-Lists
Top 50 NIH-Funded Institutions of 2022
A-Lists
Top 10 U.S. Biopharma Clusters
A-Lists
Top 10 Spatial Biology Companies
A-Lists
Top 25 Biotech Companies of 2022
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Videos
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
Companies
Novartis
Novartis
23andMe
Abbvie
AdnaGen
Agilent Technologies
Alexion Pharmaceuticals
Amgen
Astellas
AstraZeneca
Audentes Therapeutics
Berkeley Lights
Bio-Rad Laboratories
Biogen
Cancer Genetics
Catalent
Charles RIver Laboratories
Dana-Farber Cancer Institute
deCODE genetics
Dicerna
Dimension Therapeutics
Exact Sciences
Foundation Medicine
GE Healthcare
GeneInsight
Gilead Sciences
GlaxoSmithKline
Halozyme Therapeutics
Hitachi High-Technologies
Horizon Discovery Group
Human Longevity
Illumina
Jackson Laboratory
Janssen Biotech
LabCorp
Maravai LifeSciences
MD Anderson
MDxHealth
MedImmune
Memorial Sloan Kettering Cancer Center
Merck & Co
Merck KGaA
NanoString Technologies
Novartis
Pathology
PerkinElmer
PersonalizeDx
Qiagen
RayBiotech
Roche
Sanofi
shire
Sigma-Aldrich
Synthego
Takeda
Thermo Fisher Scientific
UCB Biosciences
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Base Editing
One-Time Treatment: Base Editing Shows Promise vs. SMA
Oncologics
Olema Plans Pivotal Trial for Two-Prong Breast Cancer Treatment
Gene Therapy
Gene Therapy Briefs: Cure Rare Disease CEO’s Brother Died in Clinical Trial
Gene Therapy
Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma
Financing
StockWatch: Layoffs Fail to Lift Novartis
Genome Editing
Beyond CRISPR: Precision Bio Lands Up-to-$1.5B Editing Deal with Novartis
Novartis
Novartis Eliminating 8,000 Jobs in Global Restructuring
Precision Medicine
It Takes Two: Tango Therapeutics Leverages Synthetic Lethality in Precision Cancer...
Novartis
Novartis Jumpstarts Presence in Protein Degradation with Up-to-$1.3B Dunad Collaboration
Novartis
Bleeding Edge: Anthos Pursues a Monthly Anticoagulant
Novartis
Mountain Climbing: Dyno Fights AAV Vector Immune Response with $100M
Novartis
Novartis, Artios Pharma Target Cancer in Up-to-$1.3B DDR Collaboration
Novartis
Sangamo CEO Ponders Pipeline, Reflects on Phase III ‘Proud Moment’
Novartis
A New Vision for Gene Therapy
Novartis
Novartis Taps Sangamo Zinc Finger Tech for Gene Regulation Therapies
1
2
Page 1 of 2
Scroll Up